Status:
COMPLETED
Trial of Citalopram for the Prevention of Depression
Lead Sponsor:
Marina Klein
Collaborating Sponsors:
Ontario HIV Treatment Network
Schering-Plough
Conditions:
Depression
HIV Infections
Eligibility:
All Genders
18+ years
Phase:
PHASE3
Brief Summary
With the improved prognosis of human immunodeficiency virus (HIV) infection, end stage liver disease due to hepatitis C (HCV) now represents a major cause of morbidity and mortality in people with HIV...
Detailed Description
Trial design: This study is a Canadian multicentre randomized, double-blind placebo controlled trial. We will evaluate whether prophylactic citalopram compared to symptomatic treatment of depression ...
Eligibility Criteria
Inclusion
- HIV+ adults with chronic HCV infection requiring therapy and with no contraindications to PEG-IFN/ribavirin will be enrolled.
Exclusion
- Subjects with prior suicide attempt, active depression, treatment with antidepressants within 6 months of study entry or with other psychiatric disorders will be excluded.
Key Trial Info
Start Date :
November 1 2006
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
March 1 2012
Estimated Enrollment :
76 Patients enrolled
Trial Details
Trial ID
NCT00317746
Start Date
November 1 2006
End Date
March 1 2012
Last Update
May 22 2017
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Immunodeficiency Service Montreal Chest Institute McGill University Health Centre
Montreal, Quebec, Canada, H2X 2P4